• Arvinas highlighted FDA clearance for VEPPANU (vepdegestrant), positioned as first FDA-approved PROTAC, for adults with ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer following progression on at least one line of endocrine therapy.
• Pipeline update centered on four Phase 1 PROTAC programs with near-term data, spanning neurology and oncology, including LRRK2 degradation for PSP and Parkinson’s disease.
• ARV-102 shown to reach deep-brain regions in non-human primates with up to 94% LRRK2 degradation, with Phase 1b/2 PSP trial initiation targeted in 2026, pending final chronic toxicology submission and FDA clearance.
• Partnership positioning included VEPPANU commercialization out-licensing, luxdegalutamide rights licensed to Novartis with more than $1 billion potential total deal value, with strategic partnerships generating more than $800 million in non-dilutive cash.
• Arvinas projected cash runway into 2H 2028, based on cash, cash equivalents, and marketable securities as of March 31, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arvinas Inc. published the original content used to generate this news brief on May 12, 2026, and is solely responsible for the information contained therein.